ARTHRITIS DRUGS ADVISORY COMMITTEE
August 16, 2001
(Recombinant Methionyl Human Interleukin-1 Receptor Antagonist)
The statements contained in this document are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.
Briefing Package pdf doc
Food and Drug Administration
Briefing Information pdf doc